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Abstract
Background: Besides well-established roles of bile acids (BA) in dietary lipid absorption and cholesterol homeostasis, it has
recently become clear that BA is also a biological signaling molecule. We have shown that strategies aimed at activating
TGR5 by increasing the BA pool size with BA administration may constitute a significant therapeutic advance to combat the
metabolic syndrome and suggest that such strategies are worth testing in a clinical setting. Bile acid binding resin (BABR) is
known not only to reduce serum cholesterol levels but also to improve glucose tolerance and insulin resistance in animal
models and humans. However, the mechanisms by which BABR affects glucose homeostasis have not been established. We
investigated how BABR affects glycemic control in diet-induced obesity models.
Methods and Findings: We evaluated the metabolic effect of BABR by administrating colestimide to animal models for the
metabolic syndrome. Administration of BABR increased energy expenditure, translating into significant weight reduction
and insulin sensitization. The metabolic effects of BABR coincide with activation of cholesterol and BA synthesis in liver and
thermogenesis in brown adipose tissue. Interestingly, these effects of BABR occur despite normal food intake and
triglyceride absorption. Administration of BABR and BA had similar effects on BA composition and thermogenesis,
suggesting that they both are mediated via TGR5 activation.
Conclusion: Our data hence suggest that BABR could be useful for the management of the impaired glucose tolerance of
the metabolic syndrome, since they not only lower cholesterol levels, but also reduce obesity and improve insulin
resistance.
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Introduction
Bile acid (BA) is essential constituents of bile that facilitate
dietary lipid absorption and cholesterol catabolism. BA also
activates several signaling pathways, endowing them with an
endocrine function. For instance, BA was shown to be natural
ligands that activate the nuclear receptor farnesoid X receptor
(FXR, NR1H4) [1–3], which controls both the synthesis and
enterohepatic circulation of BA [4–5]. FXR induces the expression
of the short heterodimer partner (SHP, NR0B2), an atypical
nuclear receptor that acts as a corepressor. The FXR-mediated
SHP induction contributes to the negative feedback regulation of
BA biosynthesis, through inhibition of liver X receptor a and b
(LXRa, NR1H3 and LXRb, NR1H2) and liver receptor
homolog-1 (LRH-1, NR5A2), both required for the transcription
of the rate-limiting enzyme in the neutral BA biosynthesis
pathway, cholesterol 7a-hydroxylase (CYP7A1) [6–11]. The
FXR-mediated induction of FGF15/19 (FGF19 in human and
its ortholog FGF15 in mouse) in intestinal epithelial cells also
participates in the feedback repression of BA synthesis, via FGFR4
on hepatocytes [12–14]. Using a similar mechanism, the FXR-
mediated SHP induction attenuates the capacity of LXR and
LRH-1 to induce the expression of sterol regulatory element-
binding protein (SREBP)-1c, the master regulator of lipogenesis,
explaining the inhibition of hepatic fatty acid and triglyceride
biosynthesis and VLDL production by BA administration [15].
Recently, it was reported that FXR deficiency improves glucose
homeostasis in a mouse model for the metabolic syndrome [16]. In
addition, we established that a synthetic FXR agonist (GW4064),
deteriorates metabolic control in a diet-induced obesity mouse
model [17]. These results suggest that the BA-specific nuclear
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receptor FXR is involved in the pathogenesis of the metabolic
syndrome.
BA may also signal in peripheral tissues through another
pathway involving the binding and activation of TGR5, a G
protein-coupled receptor (GPCR), leading to the induction of
intracellular cyclic adenosine monophosphate (cAMP) levels [18–
19]. The subsequent activation of type 2 iodothyronine deiodinase
(D2), the enzyme which converts inactive thyroxine into active
3,5,39-triiodothyronine [20] and hence determines thyroid hor-
mone receptor saturation in cells, and of peroxisome proliferator-
activated receptor (PPAR) c coactivator-1a (PGC-1a), the master
regulator of mitochondrial biogenesis [21], then stimulates energy
expenditure in brown adipose tissue (BAT) (in rodents) and skeletal
muscle (in humans) [22].Activation of this pathway explains how
administration of BA to mouse models of obesity and diabetes
induces weight loss and insulin sensitization. In addition, we
reported that in mice, a synthetic FXR agonist (GW4064) reduced
the BA pool and altered BA composition impairing peripheral
energy metabolism possibly via TGR5 [17]. Furthermore, TGR5
activation enhances GLP-1 secretion from the enteroendocrine L-
cell stimulating pancreatic insulin secretion [23]. Thus in addition
to FXR, the BA-specific GPCR TGR5, is an attractive therapeutic
target for treating metabolic syndrome.
These observations have built a strong case that BA has effects
beyond the strict control of BA homeostasis and function as
general metabolic integrators [24]. Bile acid binding resins
(BABR), such as cholestyramine, is effective drugs for the
treatment of coronary heart disease by lowering LDL-cholesterol
as primary prevention, and for the treatment of cholestatic liver
disease. BABR absorbs BA in the intestine thereby preventing
their uptake in the ileum and interrupting their enterohepatic
circulation. The resulting decrease of negative feedback signals will
induce the expression of Cyp7a1. The subsequent decrease in
intrahepatic cholesterol levels will on its turn activate SREBP-2,
which induces the expression of the low density lipoprotein (LDL)
receptor, to enhance cholesterol uptake, and of enzymes that
synthesize cholesterol de novo, such as 3-hydroxy-3-methylglutaryl
(HMG) CoA reductase. BABR was also reported to improve
glycemic control in a type 2 diabetes mouse model [25], but the
mechanism has not been established. We characterize here in
detail the molecular and functional impact of a second generation
BABR, colestimide [26], on metabolic homeostasis in animal
models for the metabolic syndrome. Interestingly, colestimide not
only reduces cholesterol levels but also decreases body weight and
improves glucose tolerance, qualifying BABR as ideal agents to
treat the metabolic syndrome. We suggest that a part of the anti-
metabolic syndrome effect of BABR will be exerted by an
alteration of the peripheral BA composition followed by TGR5
activation.
Materials and Methods
Materials
Cholic acid (CA) and cholestyramine were obtained from Sigma
(St. Quentin Fallavier, France). Colestimide was a generous gift of
Mitsubishi Pharmaceuticals.
Animal studies
All procedures undertaken in the present study conformed to
the principles outlined in the Guide for the Care and Use of Laboratory
Animals published by the USA National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and were approved by the
Institutional Animal Care and Use Committee of Keio University
School of Medicine (permission No. 08062-(2)). Male C57BL/6J
mice, 6–7 weeks of age, were obtained from Charles River
Laboratories France (l’Arbresle, France) and CLEA Japan Inc.
(Tokyo, Japan), respectively. All mice were maintained in a
temperature-controlled (23uC) facility with a 12 hours light/dark
cycle and were given free access to food and water. The high-fat
diet was obtained from Research diets (New Jersey, USA). The
high-fat diet (D12492) contained 20 kcal% protein, 20 kcal%
carbohydrate and 60 kcal% fat. For treatment with BA or BABR,
mice were fed diets mixed with CA (0.5% w/w) or colestimide (2%
w/w). Based on a daily food intake of 5 g, this resulted in a daily
dose of colestimide 100 mg. The mice were fasted 4 hours before
harvesting blood for subsequent blood measurements, and tissues
for RNA isolation, lipid measurements and histology. Food intake
was measured from the accumulated weight of the food for 1 week,
with 5 mice in each group. Oxygen consumption was measured
using the Oxymax apparatus (Columbus Instruments, Columbus,
OH) [27].
Morphological studies
Pieces of mouse tissues were fixed in Bouin’s solution,
dehydrated in ethanol, embedded in paraffin, and cut at a
thickness of 5 mm. Sections were deparaffinized, rehydrated, and
stained with haematoxylin and eosin.
mRNA expression analysis by Q-RT-PCR
Expression levels were analyzed in cDNA synthesized from total
mRNA using real-time PCR as described [22]. The sequences of
the primer sets used are displayed in table 1.
Clinical biochemistry and evaluation of glucose and lipid
homeostasis
An oral glucose tolerance test (OGTT) was performed in
animals that were fasted overnight. Glucose was administered by
gavage at a dose of 2 g/kg. An intra peritoneal insulin tolerance
test (IPITT) was done in 4 h fasted animals. Insulin was injected at
a dose of 0.75 U/kg. Glucose quantification was done with the
Maxi Kit Glucometer 4 (Bayer Diagnostic, Puteaux, France) or
Glucose RTU (bioMe´rieux Inc., Marcy l’Etoile, France). Plasma
insulin concentrations were measured using ELISA for mouse
(Cristal Chem Inc., Downers Grove, IL). HOMA-R was
calculated by this formula: (fasting serum insulin concentration
[mU/ml])*(fasting serum glucose concentration [mg/dl])/405.
Free fatty acids, triglycerides, and total cholesterol were deter-
mined by enzymatic assays (Roche, Mannheim, Germany). LDL
cholesterol was measured with plasma clinical chemistry analysis
using AU-400 automated laboratory workstation and commercial
reagents (Olympus France SA, Rungis, France) [28]. BA in
enterohepatic organs were determined as described [29]. Lipid
absorption was calculated as follows; (food lipid content – fecal
lipid content)/food lipid content (6100(%)), with the food and
feces consumed by/accumulated from 5 mice for 48 hours. To
calculate the lipid absorption, TG was extracted from the
accumulated feces by the classical Folch method [30] and
measured as previously described [15].
Statistical analysis
Values were reported as mean +/2 standard error (SEM).
Statistical differences were determined using ANOVA (Statsview
software, Abacus concepts, Inc., Berkeley, CA). Statistical signif-
icance is displayed as * (P,0.05) or ** (P,0.01) versus F.
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Results
BABR prevents the onset of diet-induced obesity
To evaluate the metabolic effects of a BABR in models of diet-
induced obesity (DIO), we fed C57BL/6J mice normal chow, HF
diet, or HF diet supplemented with either colestimide (2% w/w) or
cholic acid (CA, 0.5% w/w) for 96 days. HF fed animals gained
more weight than chow-fed animals. The animals fed with CA
supplemented HF diet gained weight at a rate comparable to
chow-fed mice. Colestimide had an even more pronounced effect
in curbing weight gain. Since food intake and lipid absorption
were not affected by CA and colestimide, these effects on body
weight are probably mediated by increased energy expenditure
(Fig. 1A). At necropsy, the weight of liver, epididymal white
adipose tissue (epWAT) and BAT of HF fed animals was all
significantly increased (Fig. 1B). The BAT was paler, indicative of
increased fat accumulation, and there was an expansion of WAT
surrounding the BAT (not shown). Both colestimide and CA
completely prevented HF-induced changes in liver and adipose
mass and morphology. High fat diet-induced significantly
increased serum total cholesterol (T-C), LDL-cholesterol (LDL-
C), fasting glucose and insulin levels. Colestimide ameliorated
serum triglyceride (TG), T-C, LDL-C, fasting glucose and insulin
levels significantly. CA administration exerted significant reduc-
tion of fasting glucose and insulin levels, but induced serum LDL-
C level as expected (Fig. 1C). During OGTT, both colestimide
and CA significantly reduced blood glucose concentrations to
normalize the glucose tolerance of the mice with diet-induced
obesity. Insulin sensitivity of the mice was also improved by
colestimide and CA, shown in the result of IPITT (Fig. 1D). In
KK-Ay mice, both colestimide and cholestiramine improved
metabolic status (Text S1) without suppressing their food intake
(Fig. S1A). The BABR significantly reduced epWAT weight gain,
and also significantly improved serum metabolic index including
TG, FFA, fasting glucose, insulin levels, and HOMA-R.
Colestimide administration significantly improved liver weight
gain and serum T-C level, either (Fig. S1B–D). The BABR-
received KK-Ay mice exhibited significantly lower blood glucose
during the OGTT (Fig. S1E). In the IPITT, the BABR reduced
blood glucose level, but the improvement rate described in iAUC
was not affected by the BABR administration (Fig. S1E). These
data show that BABR improves metabolic control in mouse
models for the metabolic syndrome.
BABR increases energy expenditure
The significant weight loss, in the wake of an unaltered food
intake, suggested that BABR could stimulate energy expenditure
and as such improve metabolic homeostasis. We hence analyzed
the morphology of key metabolic tissues and performed indirect
calorimetry in the C57BL/6J mice used in the HF study (see
Fig. 1). This furthermore enabled us to compare the effect of the
BABR with those of BA, which we characterized previously in this
model [15] [22]. Liver sections of HF fed animals showed more
unstained inclusions, indicative of steatosis, which were absent
when the HF diet was supplemented with colestimide or CA (not
shown and [15]). The HF diet induced significant adipocyte
hypertrophy in both epWAT, characterized by a larger adipocyte
volume (Fig. 2A), and BAT, typified by larger lipid vacuoles within
the cells. This adipocyte hypertrophy was not observed when the
HF diet was supplemented with either colestimide or CA. Electron
microscopic analysis of BAT also showed more lipid vacuoles in
HF fed animals when compared with chow fed animals or animals
receiving HF diet combined with colestimide or CA (Fig. 2A,B&C).
Compared with the HF diet, colestimide and CA supplementation
increased the number of lamellar cristae in the mitochondria
(Fig. 2C). Indirect calorimetry, showed a higher CO2 production
and O2 consumption in animals fed a HF diet with either
colestimide or CA when compared to animals on a HF or a
Table 1. Primer sequences of genes used for quantification of mRNAs by real-time PCR.
Gene Forward Primer (59R39) Reverse Primer (59R39)
18s GATGGGAAGTACAGCCAGGT TTTCTTCAGCCTCTCCAGGT
Cyp7A1 TACAGAGTGCTGGCCAAGAG TTCAAGGATGCACTGGAGAG
SHP CAAGGAGTATGCGTACCTGAAG GGCTCCAAGACTTCACACAGT
FXR CAAAATGACTCAGGAGGAGTACG GCCTCTCTGTCCTTGATGTATTG
PGC-1a AAGGGCCAAACAGAGAGAGA GCGTTGTGTCAGGTCTGATT
PEPCK GGGAACTCACTACTCGGGAA GCCAGGTATTTCTTCTTGCC
G6Pase CCGGATCTACCTTGCTGCTCACTTT TAGCAGGTAGAATCCAAGCGCGAAAC
SREBP-2 AAGTGACCGAGAGTCCCTTG ACGTTGAGACTGCTCCACAG
HMGCR TCGAAGGACGAGGAAAGACT CGTCAACCATAGCTTCCGTA
LDLR AGGCTGTGGGCTCCATAGG TGCGGTCCAGGGTCATCT
PPARa GGTGAGGAGAGCTCTGGAAG GAAGCTGGAGAGAGGGTGTC
ACC ACCCACTCCACTGTTTGTGA CCTTGGAATTCAGGAGAGGA
SCD1 CTCCTGCTGATGTGCTTCAT AAGGTGCTAACGAACAGGCT
D2 TTCTGAGCCGCTCCAAGT GGAGCATCTTCACCCAGTTT
UCP-1 GGCCCTTGTAAACAACAAAATAC GGCAACAAGAGCTGACAGTAAAT
FGF15 GGCAAGATATACGGGCTGAT GATGGTGCTTCATGGATCTG
mCPT-1 GCACTGCAGCTCGCACATTACAA CTCAGACAGTACCTCCTTCAGGAAA
Cyp8B1 GGAAGCCAAGAAGTCGTTCA GACGCAGACTCTCCTCCATC
Cyp27A1 TCTGGCTACCTGCACTTCCT CTGGATCTCTGGGCTCTTTG
doi:10.1371/journal.pone.0038286.t001
Bile Acid Binding Resins Improve Metabolic Control
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e38286
normal diet (Fig. 2D). We conclude from these experiments that
feeding of colestimide or CA changes fat and energy metabolism
most likely due to an effect on basal metabolic rate.
Molecular mechanism of BABR action
To identify the molecular drivers of the effects of BABR, we
performed analysis of gene expression using Q-RT-PCR in liver,
BAT, muscle and ileum of the C57BL/6J HF study (Fig. 1).
Hepatic gene expression reflected the interruption of the
enterohepatic cycle of BA by BABR and its consequences on BA
production and cholesterol homeostasis. These changes were
typified by the significant induction of Cyp7a1 expression,
subusequent to the reduction in Shp. Cyp8b1 expression was
significantly suppressed by CA administration, but was not
affected by BABR administration. Gene expression of Cyp27a1,
another rate-limiting enzyme participating in the alternative acidic
BA synthesis pathway, was not affected by CA or BABR
administration. The cholesterol depletion caused by colestimide
stimulated BA production by CYP7A1, and then induced
significantly increased expression levels of Srebp-2 and its target
genes including HMG-CoA reductase and LDL receptor. Genes
involved in gluconeogenesis, such as phosphoenolpyruvate car-
boxykinase (Pepck) and glucose-6-phophatase (G6Pase) were affect-
ed. Pepck gene expression was significantly induced, and G6Pase
gene expression was also stimulated as a consequence of the
significant rise in the Pgc-1a expression, which stimulates
gluconeogenesis. In contrast to colestimide, and as previously
reported, the FXR agonist CA significantly induced Shp mRNA
levels, which attenuates the expression of Cyp7a1 and of the genes
involved in cholesterol homeostasis. Genes involved in fatty acid
oxidation (Ppara) and lipogenesis (acetyl-CoA carboxylase 1 (Acc1)
and stearoyl-CoA desaturase-1 (Scd1)) were not changed in
response to colestimide and CA (Fig. 3A).
In BAT, the expression of Pgc-1a and D2 were both induced by
colestimide and CA. As a consequence the expression of
uncoupling protein-1 (Ucp-1) was also increased after both BABR
and BA administration (Fig. 3B). Colestimide and CA treatment
did not lead to significant differences in the expression of the genes
involved in energy homeostasis in muscle (Fig. 3C). In ileum, the
expression of Fgf15, which is one of the target genes of FXR, was
significantly decreased by colestimide and increased by CA
(Fig. 3D). In combination, the gene expression studies confirm
that BAT and liver are the primary target organs that contribute to
the beneficial effects of BABR on energy, lipid and glucose
homeostasis. Remarkably, the effect on energy homeostasis
induced by BABR was very similar to those observed after
administration of CA (Figs. 1, 2, 3, Fig. S1 and [22]), despite the
fact that BABR and BA has opposite actions on hepatic gene
expression. Precisely, BABR administration induces Cyp7a1
expression, while BA supplementation reduces expression of this
gene, which is secondary to the changes in the BA pool size and
serum BA levels. CA increased the BA pool and serum BA levels,
but unexpectedly colestimide induced only a minor and non
significant decrease in these parameters (Table 2). More striking,
the changes in the composition of the BA pool and serum BA was
similar after BABR or CA administration [22]. Both treatments
Figure 1. BA and BABR improve metabolic control in DIO C57BL/6J mice model. (A) Body weight, food intake and TG absorption (B) Liver,
epididymal WAT (epWAT), and BAT weight change of C57BL/6J mice during 96 days on different diets. Ch stands for chow, F denotes HF diet, FCOL
denotes HF diet+2.0% w/w colestimide and FB denotes HF diet+0.5% w/w CA. (C) Serum levels of TG, T-C, LDL-C, glucose and insulin in C57BL/6J
mice on the indicated treatments. (D) Glucose levels during OGTT and IPITT in the different treatment groups (AUC is depicted in the inset). The OGTT
were performed after an overnight fast after 9 weeks of administration. Glucose was administered by gavage at a dose of 2 g/kg. The IPITT were
performed after 4 h fast after 10 weeks of administration. Insulin was injected at a dose of 0.75 U/kg. Data are expressed as the mean +/2 SEM (n = 5–
6). * (P,0.05) or ** (P,0.01) versus F.
doi:10.1371/journal.pone.0038286.g001
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increased the relative contribution of CA and its derivatives, most
notably tauroCA. Bile acids derived from chenodeoxyCA such as
tauromuriCA were decreased by both BA supplementation and
BABR treatment (Fig. 4 and [22]). BABR preferentially sequesters
mono- and di-hydroxy BA and prevent them from enterohepatic
recirculation hence inducing the de novo synthesis of CA.
Discussion
In the present study, we show that administration of BABR
stimulated energy expenditure mediated by BAT, thereby
preventing and reversing diet-induced obesity in mice. This
phenomenon was accompanied by an improved glucose tolerance
and insulin sensitization in a diet-induced obesity model
(C57BL6/J (Fig. 1)). BABR also improved glucose tolerance in
KK-Ay mice (Text S1 and Fig. S1). Brown adipose tissue is
recently recognized as an important tissue of thermogenesis and
energy homeostasis not only in rodents but also in man [31–33].
Our results indicate that therapy with colestimide, a new and
better formulated BABR when compared with cholestyramine,
could improve metabolic control also in humans suffering from the
metabolic syndrome. In fact, colestimide decreased fasting glucose
levels, but also reduced body weight, BMI, and visceral fat mass
[34]. Furthermore, BABR was reported to improve obesity, insulin
sensitivity and glycemic control in diabetes mellitus mouse model
[25]. Furthermore, there is clinical evidence suggesting that BABR
such as colesevelam may improve both lipid control and glycemic
control in patients with type 2 diabetes that receive oral
antihyperglycemic medications [35–37] [38,39]. Combined with
the limited systemic toxicity ofBABR, which isnot absorbed, these
compounds could constitute a significant advance in our
therapeutic armamentarium to combat against metabolic syn-
drome. Although there is some evidence that the beneficial effects
of BABR may be mediated through FXR, LXR, FGF15/19, and
TGR5, but the exact molecular mechanisms are not yet clearly
defined.
On a molecular and cellular level, BABR improves metabolic
homeostasis through effects on liver and BAT (Fig. 5). The effects
on liver are well known and include an induction of cholesterol
and BA biosynthesis, subsequent to the fecal loss of bile acids
caused by the BABR treatment. This underlies the cholesterol-
lowering effect of BABR. The metabolic effects on BAT have not
been reported before and phenocopy the changes seen after
treatment of rodents with primary BA, such as CA [22]. This is
surprising, since treatment with BABR and BA has opposite
actions on most parameters of BA homeostasis. CA administration
increases FXR activation, whereas BABR treatment decreases it.
CA administration decreases the BA synthesis, whereas BABR
treatment increases it. However, BABR and CA had similar effects
on BA composition. Both treatments increased the relative
contribution of CA and its derivatives, most notably deoxyCA,
tauro-deoxyCA and tauroCA. Bile acids derived from chenodeox-
Figure 2. BABR increase energy expenditure. Hematoxylin and eosin (HE) stained epWAT (A) and BAT (B) sections of C57BL/6J animals treated
with control or HF diet when indicated combined with colestimide or CA as specified in Fig. 1. Scale bar, 50 mm. (C) BAT analysis by transmission
electron microscopy. (D) Averaged O2 consumption (VO2) and CO2 production (VCO2) as measured by indirect calorimetry in mice on the different
diets as indicated. Data are expressed as the mean +/2 SEM (n = 5–6). * (P,0.05) or ** (P,0.01) versus F.
doi:10.1371/journal.pone.0038286.g002
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yCA such as muriCA and tauromuriCA were decreased. In
addition to our studies in mice, colestimide treatment of
hypercholesterolemia patients significantly increased CA in bile
[40]. The most likely explanation for this specific increase in BA
species derived from CA, is the fact that colestimide has a high
adsorptive capacity for mono- and di-hydroxy BA like chenodeox-
yCA and lithoCA, but a relative low capacity for the tri-hydroxy
BA such as CA. In addition, the induced BA biosynthesis during
colestimide treatment might produce more CA than chenodeox-
yCA [41]. Increased BA pool size and plasma BA levels are fine
indicator for TGR5 activation [22] [17]. This time, we focus on
the importance of bile acid composition to improve metabolic
status. TGR5 is activated by almost all BA including mono- and
di-hydroxy BA. Some of the BA like ursodeoxyCA have little
activity on TGR5, but no inhibitory BA was identified in our test
of over 60 BA and BA derivatives for antagonistic effects on TGR5
(data not shown). Most importantly, BABR administration
induced levels of tauroCA, a relatively potent TGR5 agonist
[22], which could be the key to the anti-metabolic syndrome effect
of BABR administration. In agreement with this, reduction of BA
pool size and tauroCA levels by the administration of the synthetic
FXR agonist GW4064, exacerbated the effects of HF feeding [17].
It is conceivable that BABR, such as colestimide and
cholestyramine that are mainly active in the intestinal tract, could
affect the production of incretins, such as FGF15, cholecystokinin
(CCK) and glucagon like peptide-1 (GLP-1). FGF15 is interesting
in this respect, since transgenic mice that overexpress the human
Fgf15 ortholog Fgf19 in the muscle or in a more general pattern
have increased metabolic rate and decreased adiposity [42].
BABR, however, decreases expression of Fgf15 (Fig. 3D), whereas
CA has the opposite effect, making it unlikely that it underlies the
common metabolic effects of BABR. GLP-1 has glucose-depen-
dent insulinotropic actions on the pancreatic beta-cells and has
recently been associated with bile acids because its release was
stimulated in an enteroendocrine cell line via TGR5, a GPCR
specific for bile acids [23]. BABR may have an effect on the
intestinal secretion of GLP-1, according to recent reports [43].
Indeed, we found that GLP-1 secretion was stimulated by BABR
administration (unpublished data), which may contribute to the
other beneficial effects of BABR. CCK is another good candidate,
since cholestyramine can increase CCK production but also
pancreatic beta cell function [44–45]. In addition CCK has been
linked to increased sympathetic activity to BAT [46–47]. To date,
effects of BABR on incretins and BAT have not been sufficiently
studied.
Taken together, our data show that BABR activates energy
expenditure, resulting in weight loss and improved glucose
tolerance in animal models suffering from the metabolic
syndrome, in a mechanism very similar to BA administration
[22]. The alteration of BA composition, which occurs after BABR
Figure 3. Gene expression in liver, BAT, muscle and ileum. (A) mRNA expression levels of Cyp7a1, Cyp8b1, Cyp27a1, Shp, Fxr, Pgc-1a, Pepck,
G6Pase, Srebp-2, HMG-CoA reductase, LDL-Receptor, Ppara, Acc1 and Scd1 were determined using quantitative RT-PCR in liver of C57BL/6J mice
treated as described in Fig. 1A. (B) mRNA expression levels of D2, Pgc-1a and Ucp-1 in BAT. (C) Pgc-1a and mCpt-1 in muscle. (D) Fgf15 in ileum.
Treatments and abbreviations are identical to those specified in Fig. 1A. Mice were fasted 4 hours before sacrifice and tissue collection. Data are
expressed as the mean +/2 SEM (n= 5–6). * (P,0.05) or ** (P,0.01) versus F.
doi:10.1371/journal.pone.0038286.g003
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and CA administration, more specifically the increase of tauroCA,
may be the key to improve the metabolic status. A recent study in
man employing colesevalam treatment in type 2 diabetic patients
revealed no correlation energy expenditure with plasma BA levels
[48]. Another report showed that BA kinetics caused by BABR
administration could not affect the improvement of glycemic
control in patients with T2DM [49]. In fact, biophysiological roles
and significances of the each composition of the BA profiles might
not be identical in human and mice, and it is difficult to make a
plain comparison between the report and our result. Futhermore,
in the report, the ‘BA kinetics’ was just a cholic acid or total bile
acid synthesis. More precise analysis according to BA profiles, as
we performed in this article, would provide a clue to solve the
mechanism of improved glycemic control by BABR. These reports
illustrate that the mechanisms involved in the beneficial effects of
BABR in humans are still controversial and further investigation is
warranted. Our previous study demonstrated one of the various
mechanisms of BABR in anti-metabolic syndrome effect. Our
Figure 4. Bile acid composition in the enterohepatic organs and serum. Bile acid composition in the enterohepatic organs and serum of
C57BL/6J fed with high fat diet (Fig. 1A) after treatment with colestimide or CA. Undefined abbreviations are: G, glycol; T, tauro; CD, chenodeoxy; D,
deoxy; H, hyo; HD, hyodeoxy; UD, ursodeoxy; L, litho; M, muri.
doi:10.1371/journal.pone.0038286.g004
Table 2. BA pool size and serum BA concentration in C57BL/
6J mice.
BA pool size (nmol/g
Liver+Intestine) Serum BA (mM)
Ch 9852.6+/2191.2A 15.23+/22.23
F 9130.4+/2261.6 13.83+/21.80
FCOL 8643.4+/2254.8 11.84+/21.68
FB 22867.0+/2145.3B 18.21+/21.16A
Ch denotes chow, F denotes HF diet, FCOL denotes HF diet+2% w/w
colestimide and FB denotes HF diet+0.5% w/w CA as specified in Fig. 1A.
Data are expressed as mean +/2 SEM (n = 5–6).
AP,0.05 versus F.
BP,0.01 versus F.
doi:10.1371/journal.pone.0038286.t002
Figure 5. Changes in energy metabolism by BABR administra-
tion. Administration of BABR to animals leads to induction of bile acid
synthesis and as a consequence a relative increase in CA and TCA. This
translates into induced energy expenditure in brown adipose tissue,
hence improving obesity and diabetes.
doi:10.1371/journal.pone.0038286.g005
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findings in mice could be useful clues to elucidate the signaling
functions of BA in man.
Supporting Information
Figure S1 BABR improves metabolic control in KK-Ay
mice. (A) Body weight (BW) and food intake change of KK-Ay
mice. Ch denotes chow, COL denotes chow+colestimide and
CHO denotes chow+cholestyramine. (B) A comparison of the
weight of liver, epididymal WAT (epWAT) and BAT fat pads after
the different interventions. (C) Serum levels of triglycerides (TG),
free fatty acids (FFA), total cholesterol (T-C) in KK-Ay mice on the
indicated treatments. (D) Serum levels of glucose and insulin in
KK-Ay mice on the indicated treatments. The HOMA-IR is
calculated as described in the materials and methods. (E) Glucose
levels during an OGTT and IPITT, and area under the curve
(AUC) and integrated areas under the curve (iAUC) in KK-Ay
mice in the different treatment groups. The OGTT were
performed after an overnight fast after 2 weeks of administration.
Glucose was administered by gavage at a dose of 1 g/kg. The
IPITT were performed after 4 hours fast after 3 weeks of
administration. Insulin was injected at a dose of 0.75 U/kg. Data
are expressed as the mean +/2 SEM (n= 5–6). # (P,0.05) or
## (P,0.01) versus Ch. Further description about the materials
and methods of the experiments is included in ‘‘Materials and
Methods S1’’.
(DOC)
Text S1
(DOCX)
Materials and Methods S1
(DOC)
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